GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » DexTech Medical AB (XSAT:DEX) » Definitions » Net Intangibles Purchase And Sale

DexTech Medical AB (XSAT:DEX) Net Intangibles Purchase And Sale : kr0.00 Mil (TTM As of Mar. 2025)


View and export this data going back to 2014. Start your Free Trial

What is DexTech Medical AB Net Intangibles Purchase And Sale?

Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

DexTech Medical AB's net Intangibles purchase and sale for the three months ended in Mar. 2025 was kr0.00 Mil. Its net Intangibles purchase and sale for the trailing twelve months (TTM) ended in Mar. 2025 was kr0.00 Mil.

DexTech Medical AB Net Intangibles Purchase And Sale Historical Data

The historical data trend for DexTech Medical AB's Net Intangibles Purchase And Sale can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DexTech Medical AB Net Intangibles Purchase And Sale Chart

DexTech Medical AB Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Net Intangibles Purchase And Sale
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.60 -0.64 -3.12 -8.71 -5.39

DexTech Medical AB Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Net Intangibles Purchase And Sale Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

DexTech Medical AB Net Intangibles Purchase And Sale Calculation

Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Net Intangibles Purchase And Sale for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DexTech Medical AB Net Intangibles Purchase And Sale Related Terms

Thank you for viewing the detailed overview of DexTech Medical AB's Net Intangibles Purchase And Sale provided by GuruFocus.com. Please click on the following links to see related term pages.

DexTech Medical AB Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » DexTech Medical AB (XSAT:DEX) » Definitions » Net Intangibles Purchase And Sale
Comparable Companies
OSTO:SPAGO OSTO:ATORX OSTO:BIOSGN OSTO:BIOVIC B OSTO:NXTCL OSTO:PILA OSTO:SIMRIS B OSTO:NICA OSTO:ACOU XSAT:CHOSA VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
N/A
Address
Dag Hammarskjolds Vag 34A, Uppsala, SWE, 752 37
Website
https://www.dextechmedical.com
DexTech Medical AB develops candidate medications with applications within urological oncology, for prostate cancer. Its medication candidates include GuaDex, OsteoDex, and SomaDex, among others. The company conducts operations in medical research with the development of new drug candidates mainly in urological oncology, but also other cancer diseases and for non-malignant diseases. The company has a well built clinical base with valuable specialist expertise from research laboratories and manufacturing to clinical oncology.